Picture of Protagonist Therapeutics logo

PTGX — Protagonist Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Protagonist Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 50 cents​​ per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -68 cents.  The mean expectation of six analysts
for the quarter was for a loss of 60 cents per share. Wall
Street expected results to range from -81 cents to 5 cents per
share.
    * Revenue was $4.17 million​; analysts expected $8.00
million. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 50 cents​.
    * The company reported a quarterly loss of $30.62 million.
    * Protagonist Therapeutics Inc shares had risen by 3.3% this
quarter and gained 56.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 342%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $48.00 
This summary was machine generated from LSEG data August 6 at
01:10 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.60          -0.50          Beat
 Mar. 31 2024      1.19           3.26           Beat
 Dec. 31 2023      -0.03          0.44           Beat
 Sep. 30 2023      -0.69          -0.58          Beat

Recent news on Protagonist Therapeutics

See all news